Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Per milligram of active substance, TB-500 (10 mg per vial) is more cost-effective than BPC-157 (5 mg per vial)
The number of treatments required varies depending on the specific procedure and individual needs
Cost-effectiveness analysis indicates tirzepatide requires a 30% price reduction to meet standard thresholds, while semaglutide needs an 80% price cut from current levels
These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
In its annual report, Boehringer shared that Jardiance was the companys best-selling product in 2024
US$ 28.05
US$ 21.00
US$ 20.12
US$ 25.01
US$ 22.03
